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Abstract
Background: Data concerning antimalarial combination treatment for uncomplicated malaria in
Madagascar are largely lacking. Randomized clinical trial was designed to assess therapeutic
efficacies of chloroquine (CQ), amodiaquine (AQ), sulphadoxine-pyrimethamine (SP), amodiaquine
plus sulphadoxine-pyrimethamine combination (AQ+SP) and artesunate plus amodiaquine
combination (AQ+AS).
Methods: 287 children between 6 months and 15 years of age, with uncomplicated falciparum
malaria, were enrolled in the study. Primary endpoints were the day-14 and day-28 risks of
parasitological failure, either unadjusted or adjusted by genotyping.
Results: All treatment regimens, except for CQ treatment, gave clinical cure rates above 97% by
day-14 and 92% by day-28 (PCR-corrected). AQ+SP was as effective as AQ+AS. The risk of new
infection within the month after therapy was generally higher for AQ+AS than AQ+SP.
Conclusion: These findings show that the inexpensive and widely available combination AQ+SP
may be valuable in for the treatment of uncomplicated malaria in Madagascar and could have an
important role in this country, where much of the drugs administered go to patients who do not
have malaria.
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Background
Malaria remains one of the most serious health problems
worldwide and a leading cause of childhood morbidity
and mortality, especially in Africa [1]. At least 300 million
clinical cases of malaria occur each year, resulting in more
than a million child deaths worldwide. Early diagnosis
and prompt effective treatment remain the cornerstone
for the reduction of malaria-related morbidity and mor-
tality [2]. However, efforts to control malaria in Africa
have been severely compromised by the emergence of
resistance in Plasmodium falciparum to the inexpensive and
widely used drugs, chloroquine (CQ) and sulphadoxine-
pyrimethamine (SP) [3,4]. As a consequence, the use of
combination antimalarial therapy has been widely advo-
cated [5]. Of the available antimalarial drugs, the artem-
isinins are the most potent and the World Health
Organization (WHO) specifically advocates the use of
artemisinin-based combination therapy (ACT) as the
standard policy for the treatment of uncomplicated falci-
parum malaria [6]. ACTs give a rapid clinical and parasi-
tological response, may delay the development of
resistance and may reduce malaria transmission by killing
gametocytes. However, there are concerns regarding the
cost and availability of artemisinin-based combination
therapy (ACT), and only limited data comparing ACT
with other combination therapies in Africa are available
[7]. Moreover, it is unclear whether ACTs are appropriate
for empirical management of febrile illnesses outside the
formal health sector without laboratory confirmation, in
the way that CQ and SP have been used for several years.
Malaria treatment in Madagascar is in transition: for over
50 years, malaria was treated successfully using chloro-
quine (CQ) as first-line treatment. In 2005, the National
Malaria Control Programme (NMCP) decided to revise its
treatment policy and to replace CQ with artemisinin-
based combination therapy (AQ+AS, artesunate plus
amodiaquine combination) with the support of resources
from the Global Fund. This choice was guided by the rec-
ommendations of WHO and data from the most recent
clinical trial based on the WHO standard protocol [8]: the
trial was conducted on the island of Sainte Marie in 2004
and has demonstrated clinical failure in 36.9% of cases
within two weeks of CQ treatment. Alternatives to ACTs,
which include the non-artemisinin-based combination
therapy (NACT) amodiaquine plus sulphadoxine/
pyrimethamine (AQ+SP), were surprisingly not consid-
ered, although the WHO's Roll Back Malaria programme
had recommended the use of NACT in settings where the
efficacy of both component drugs is high; this was the case
in Madagascar [9,10].
Few data is available concerning alternative or combina-
tory antimalarial treatment in uncomplicated malaria in
Madagascar. Randomized clinical trial was designed (i) to
update knowledge about the therapeutic efficacies of CQ
(used for the home management of presumed malaria in
children under the age of five years), AQ and SP alone
(used for intermittent preventive treatment in pregnant
women), (ii) to compare the respective therapeutic effica-
cies of two combinatory treatments, AQ+SP and AQ+AS,
and (iii) to generate data which could be used as a guide
for designing a rational antimalarial treatment policy in
Madagascar.
Materials and methods
Study design and study sites
The study was conducted between February and June
2006 during and at the end of the rainy season, in primary
health centres of Moramanga and Saharevo in the east
foothill areas of the Highlands of Madagascar. In this area,
malaria transmission is low and predominantly seasonal.
The main vector is Anopheles funestus and the number of
infective bites associated with Plasmodium falciparum is
estimated at < 10 per person per year. The study protocol
was reviewed and approved by the Ethics Committee of
the Ministry of Health of Madagascar (N°007/SANPF/
2007).
Patients
Children between six months and 15 years of age present-
ing at primary health centres of Moramanga and Saharevo
were enrolled in the study if they met the following inclu-
sion criteria [11]: (i) monoinfection with P. falciparum at
a parasitaemia between 1,000 and 200,000/μl, (ii) axillary
temperature  ≥ 37.5°C, (iii) body weight > 5 kg, (iv)
absence of severe malnutrition, (v) absence of febrile con-
ditions caused by diseases other than malaria, (vi)
absence of 'danger signs' (inability to stand, breastfeed or
drink; recent convulsions; lethargy or persistent vomiting)
and of severe and complicated malaria, (vii) haemoglobin
(Hb) ≥ 5 g/dl, and (viii) informed written consent of par-
ents/guardians.
Exclusion criteria were: (i) known hypersensitivity to SP,
AQ, or AS, (ii) detection, during follow-up of mixed
malarial infections, and (iii) development of concomitant
disease which would interfere with the classification of
treatment outcome.
Treatments, randomization and blinding
Patients were randomly assigned to receive one of five oral
therapies: CQ (10 mg/kg on days 0 and 1, and 5 mg/kg on
day 2); AQ (10 mg/kg on days 0, 1, and 2); SP (25 mg/kg
sulphadoxine and 1.25 mg/kg pyrimethamine as a single
dose on day 0); AQ + SP or AQ + AS (4 mg/kg on days 0,
1, and 2). Randomization was performed in blocks of five,
and treatment regimens were allocated by an independent
individual not involved in the analysis of the study.Malaria Journal 2007, 6:65 http://www.malariajournal.com/content/6/1/65
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All other study personnel were blinded to the treatment
assignments, and patients were not informed of their
treatment regimen. Patients were directly observed for 30
minutes after treatment, and the dose was readministered
if vomiting occurred. Patients who repeatedly vomited
their first dose of study medication were excluded from
the study.
Follow-up procedures and classification of treatment 
outcomes
Following enrollment, patients were asked to return for
follow-up visits on days 1, 2, 3, 7, 14, 21, 28, and any
other day if they felt ill. Blood was obtained by finger
prick for thick blood smears and storage on filter paper on
all follow-up days. Haemoglobin was determined on day
0 and on day 28. Treatment outcomes were classified
according to 2003 WHO guidelines as Early Treatment
Failure (ETF; danger signs or complicated malaria or fail-
ure to adequately respond to therapy on days 0–3), Late
Clinical Failure (LCF; danger signs or complicated malaria
or fever and parasitaemia on days 4–28 without previ-
ously meeting criteria for ETF), Late Parasitological Failure
(LPF; asymptomatic parasitaemia on days 4–28 without
previously meeting criteria for ETF or LCF), and Adequate
Clinical and Parasitological Response (ACPR; absence of
parasitaemia on day 28 without previously meeting crite-
ria for ETF, LCF, or LPF) [11].
Patients classified as having suffered treatment failure
were treated with quinine (10 mg/kg three times daily for
7 days); however, their response to repeat therapy was not
assessed. Patients were excluded after enrollment if any of
the following occurred: (1) use of antimalarial drugs out-
side of the study protocol; (2) parasitaemia in the pres-
ence of a concomitant febrile illness; (3) withdrawal of
consent; (4) loss to follow-up, (5) protocol violation, or
(6) death due to a non-malaria illness.
Laboratory procedures
Blood smears were stained with 4 % Giemsa for 20 min.
Parasite densities were determined from thick blood
smears by counting the number of asexual parasites per
200 WBCs (or per 500, if the count was less than 10 para-
sites/200 WBCs), assuming a WBC count of 8,000/μl. A
smear was considered negative if no parasites were seen
after review of 100 fields. Thin blood smears were used to
detect non-falciparum infections. Gametocytes were
counted against 500 WBC for 287 children at enrolment
and in 258, 257, 220, 217 specimens available for that
purpose collected on day 7, day 14, day 21 and day 28,
respectively. A portable spectrophotometer (HemoCue©,
Anglholm, Sweden) was used for haemoglobin assays.
Molecular genotyping techniques were used to distin-
guish recrudescence from new infection for all patients
failing therapy after day 7. Briefly, filter paper blood sam-
ples collected on the day of enrollment, on day 1 and on
the day of failure were analyzed for polymorphisms in the
genes for merozoite surface protein-1 (MSP-1) and mero-
zoite surface protein-2 (MSP-2) using nested-PCR as pre-
viously described [12]. First, MSP-2 genotyping patterns
on the day of failure were compared with those at treat-
ment initiation and on day 1, using Quantity One© soft-
ware (BioRad laboratories, Inc., 1000 Alfred Nobel Drive,
Hercules, CA 94547, United States). If all of the MSP-2
alleles present on the day of failure were present at the
time of treatment initiation or on day 1, genotyping was
repeated using MSP-1. An outcome was defined as recru-
descence if all MSP-1 and MSP-2 alleles present at the time
of failure were present at the time of treatment initiation
or on day 1, and defined as a new infection otherwise.
Statistical analysis
Data were entered and verified using EpiInfo 6.04© soft-
ware (Centers for Disease Control and Prevention,
Atlanta, Georgia, United States), and analysed using Med-
Calc© software version 9.1.0.1 (MedCalc Software, Broek-
straat 52, 9030 Mariakerke, Belgium).
Analysis of treatment outcome was per protocol, which
only included patients with treatment outcomes. Fre-
quencies were compared by chi-squared tests and Fisher
exact tests, and continuous variables by Student's t-tests,
Mann-Whitney U-tests, analysis of variance or Kruskal-
Wallis tests as applicable. All reported p-values are two-
sided, without adjustment for multiple testing, and were
considered statistically significant if less than 0.05.
Results
695 patients were screened for inclusion in the study and
287 patients were randomized to receive CQ, AQ, SP, AQ
+ SP or AT + AQ (Figure 1). The baseline characteristics of
the patients assigned to the five treatment regimes were
similar (Table 1).
Clinical and parasitological monitoring was complete for
96.1% (276/287) until day 14 of follow-up and for 92.3%
(265/287) until day 28. Seventeen patients (5.7%) were
lost to follow-up, four patients withdrew consent (1.3%)
and one patient (0.3%) had to be withdrawn because he
was treated outside the study with drugs active against
malaria (Figure 1).
No severe side-effects attributable to the study medication
were observed during the follow-up period, except that
one patient treated with AQ+SP developed vomiting.
The efficacy of test drugs against uncomplicated falci-
parum malaria is shown in Table 2. All treatment regi-
mens, except for the CQ treatment group, resulted inMalaria Journal 2007, 6:65 http://www.malariajournal.com/content/6/1/65
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clinical cure rates above 97% by day-14 and 92% by day-
28 (PCR-corrected). ETF was significantly less common in
the two combinatory treatment (AQ+SP and AQ+AS)
groups than in the CQ group on day 14 and day 28 (PCR-
corrected and -uncorrected); LCF was significantly less
common in AQ, SP, AQ+SP and AQ+AS treatment groups
on day 14 and in SP, AQ+SP and AQ+AS on day 28 (PCR-
uncorrected) and in only the two combinatory treatments
on day-28 (PCR-corrected); ACPR to AQ, SP, AQ+SP and
AQ+AS did not differ significantly on day-14 or day-28
(PCR-uncorrected and -corrected).
The proportion of re-infections among recurring parasi-
taemia was higher with CQ (11.1%; 4/36) and AQ
(11.1%; 4/36) than with AQ+SP (1.2%; 1/79; P = 0.04)
(Table 2).
Parasite clearance was more effective with AQ+AS than
CQ, AQ or AQ+SP and with SP than CQ until day 2, but
less effective with AQ+AS than AQ+SP on day 28 (Figure
2).
Fever clearance was delayed with SP alone, the proportion
of febrile children being significantly lower with AQ+AS
and AQ+SP until day-2 and day-1, respectively (Figures 2
and 3).
On day-28, the extent of haematological recovery
(median of individual increases in Hb) did not differ sig-
nificantly between the five groups (CQ, 0.8 g/dl, -0.8 to
3.4; SP, 1.2 g/dl, -1.0 to 5.8; AQ, 0,9 g/dl, -3.6 to 4.1;
AQ+SP, 0.5 g/dl, -4.4 to 5.8; AQ+AS, 1.1 g/dl, -2.6 to 5.2).
Table 1: Baseline characteristics of patients
Treatment group
Parameters CQ AQ SP AQ+SP AQ+AS
No. of patients 42 39 40 83 83
No. females (%) 20 (47.6%) 22 (56.4%) 26 (65.0%) 42 (50.6%) 38 (46.3%)
Mean age (months. range) 3.8 (0.6–14) 3.3 (0.7–13) 3.8 (0.5–12) 3.9 (0.8–15) 3.9 (0.5–15)
Mean weight (kg. range) 12.9 (7–35) 13.0 (7.8–40) 12.1 (6–34) 14.3 (7–50) 14.6 (6–54.5)
Mean temperature (°C. range) 38.4 (37.5–40.4) 38.4 (37.5–40.8) 38.5 (37.5–40.8) 38.6 (37.5–41.0) 38.6 (37.5–40.9)
Geometric mean parasite density (/μl. range) 21156 (1020–199058) 25559 (1142–199800) 25640 (1010–199531) 22368 (1050–199048) 22905 (1005–184881)
Previous antimalrial therapy (%) 2 (4.7%) 1 (2.9%) 2 (5.0%) 2 (3.9%) 3 (5.3%)
Mean haemoglobin (g/dl. range) 10.1 (6.2–14.0) 10.0 (6.4–14.2) 9.7 (6.2–12.4) 10.2 (6.2–15.6) 10.4 (6.2–15.5)
CQ. Chloroquine; AQ. Amodiaquine; SP. Sulphadoxine-pyrimethamine; AS. artesunate.
Trial profile Figure 1
Trial profile.
Day 0 42 CQ 39 AQ 40 SP 83 AQ+SP 83 AQ+AS 287
01201 4
Excluded 1 1
20022 6
Evaluable by Day 
14
39 38 38 81 80 276
00000 0
32024 11
Evaluable by Day 
28
36 36 38 79 76 265
399 not malaria
    9 non-falciparum malaria
287 randomised
695 screened
Withdrew consent
Did not attend follow-up
Withdrew consent
Did not attend follow-upMalaria Journal 2007, 6:65 http://www.malariajournal.com/content/6/1/65
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Gametocyte prevalence at enrolment was 5.6% (16/287)
with a geometric mean density of 124.7 gametocytes/μl
(95% confidence interval, 50.5–307.9). There were no sig-
nificant differences at enrolment in gametocyte preva-
lence or density with respect to treatment regime (Table
3). Treatment with SP gave significantly higher gameto-
cyte prevalence on day-7 and on day-14 than the other
treatments. On day-21, gametocyte prevalence in SP
group was significantly higher than the two combinatory
treatments (AQ+SP and AQ+AS).
Discussion
The main objective of this study was to compare, for the
first time in Madagascar, the efficacy of two different com-
bination therapies: AQ+SP, an inexpensive regimen that
has proven to be efficacious in recent studies [13-16] and
AQ+AS, an ACT regimen chosen by National Malaria
Control Programme (NMCP) as first-line treatment for
uncomplicated malaria. This clinical trial was designed to
include follow-up for children in each treatment group
enrolled within 28 days because it had been shown that
antimalarial drug efficacy studies that limit follow-up to
14 days or less may significantly underestimate the risk of
re-emergence [17].
The findings are the preliminary results of an extended
study of the efficacy of antimalarial drugs for the treat-
ment of uncomplicated falciparum malaria, which
involves eight sites with differing levels of transmission
intensity across Madagascar. The methodology used was
based on the 2003 WHO protocol [11], with some modi-
fications (compromise between the high transmission
and the low to moderate transmission protocols): (i) chil-
dren enrolled in the study were between 6 months and 15
years of age and (ii) of P. falciparum parasitaemia on inclu-
sion was between 1,000 and 200,000/μl.
Proportions of febrile patients following treatment Figure 2
Proportions of febrile patients following treatment. 
CQ, Chloroquine, AQ, Amodiaquine; SP, Sulfadoxine-
Pyrimethamine; AS, artesunate; On day 1, Significant differ-
ence to SP group (P < 0.05), SP vs. AQ+SP, SP vs. AQ+AS; 
At day 2, Significant difference to SP group (P < 0.05), SP vs. 
AQ+AS; On day 14, Significant difference to CQ group (P < 
0.05), CQ vs. AQ, CQ vs. SP, CQ vs. AQ+SP, CQ vs. 
AQ+AS
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Table 2: Classification of treatment outcome
Treatment group
Treatment 
outcome
CQ AQ SP AQ+SP AQ+AS
14-day follow-up
ETF (%) 4/39 (10.3) 0/38 (0) 0/38 (0) 0/81 (0)* 0/80 (0)*
LCF (%) OTF (%) 7/39 (17.9) 14/39 
(35.9)
0/38 (0)* 0/38 
(0)
0/38 (0)* 1/38 
(2.6)
0/81 (0)* 1/81 
(1.2)
0/80 (0)* 0/80 (0)
LPF (%) 3/39 (7.7) 0/38 (0) 1/38 (2.6) 1/81 (1.2) 0/80 (0)
ACPR (%) 25/39 (64.1) 38/38 (100)* 37/38 (97.4)* 80/81 (98.8)* 80/80 (100)*
28-day follow-up non adjusted (PCR-uncorrected)
ETF (%) 4/36 (11.1) 0/36 (0) 0/38 (0) 0/79 (0)* 0/76 (0)*
LCF (%) OTF (%) 9/36 (25.0) 20/36 
(55.5)
3/36 (8.3) 5/36 
(13.9)
0/38 (0)* 2/38 
(5.2)
2/79 (2.5)* 4/79 
(5.0)
3/76 (3.9)* 12/76 
(15.7)
LPF (%) 7/36 (19.4) 2/36 (5.6) 2/38 (5.2) 2/79 (2.5)* 9/76 (11.8)
ACPR (%) 16/36 (44.5) 31/36 (86.1)* 36/38 (94.8)* 75/79 (95.0)* 64/76 (84.3)*
28-day follow-up adjusted (PCR-corrected)
New infections (%) 4/36 (11.1) 4/36 (11.1) 1/38 (2.6) 1/79 (1.2)** 6/76 (7.9)
ETF (%) 4/36 (11.1) 0/36 (0) 0/38 (0) 0/79 (0)* 0/76 (0)*
LCF (%) OTF (%) 7/36 (19.4) 13/36 
(44.4)
1/36 (2.8) 1/36 
(2.8)
0/38 (0) 1/38 
(2.6)
1/79 (1.3)* 3/78 
(3.8)
1/76 (1.3)* 6/76 (7.9)
LPF (%) 5/36 (13.9) 0/36 (0)* 1/38 (2.6) 2/79 (2.5)* 5/76 (6.6)
ACPR (%) 20/36 (55.6) 35/36 (97.2)* 37/38 (97.4)* 76/79 (96.2)* 70/76 (92.1)*
Data presented are cumulative, failures up to day 14 of follow-up are also considered in the calculation of day 28 failure rates.
Percentages are rounded to achieve totals of 100%.
CQ, Chloroquine; AQ, amodiaquine; SP, Sulphadoxine-pyrimethamine; AS, artesunate ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; 
ACPR, adequate clinical and parasitological response.
* Significant difference to CQ group (P < 0.05); ** Significant difference to CQ and AQ groups (P < 0.05).Malaria Journal 2007, 6:65 http://www.malariajournal.com/content/6/1/65
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The first step was to update data concerning therapeutic
efficacies of CQ, AQ and SP alone, because CQ is has long
been widely used in Madagascar and recommended by
the NMCP for the home management of presumed
malaria in children under five years of age (HMM). Pre-
packaged presentations of chloroquine are currently avail-
able for children from six to 11 months of age and for chil-
dren from 12 to 59 months of age and either sold at an
affordable price of US $0.025 (PaluStop®) or freely distrib-
uted at primary public health facilities (Ody Tazomoka®)
[18]. SP has also been used, since 2005, for intermittent
preventive treatment in pregnant women in all areas of
Madagascar except the Central Highlands.
No severe side-effects attributable to study medication
were found during the follow-up period in any of the
treatment groups. CQ was significantly less effective than
SP, AQ, AQ+SP and AQ+AS in treating uncomplicated fal-
ciparum malaria, with overall treatment failure of 35.9%
within 14 days of follow up and 44.4% within 28 days
(PCR-corrected). These data show a higher prevalence of
chloroquine resistance than reported in previous studies
[19-21] and a good effectiveness of SP and AQ, as had
been observed in many areas in West Africa [22,23]. These
results confirm the urgent need to replace pre-packaged
CQ with another pre-packaged effective therapy. Accord-
ing to the NMCP of the Ministry of Health of Madagascar,
this switch will be gradual with the introduction of pre-
packaged artemisinin-based combination therapies (co-
formulated presentation of the AQ+AS combination,
COARSUCAM©, Sanofi-Synthélabo Groupe, Paris, France)
from the beginning of 2008.
This study also confirms that the assumption that ACTs
are always more effective than NACTs is not always true
especially in settings, such as Madagascar, where SP or AQ
monotherapies remain effective. It was observed that
AQ+SP was as effective as AQ+AS, consistent with previ-
ous reports in Africa both in high transmission [14,15,24]
and in low transmission areas [16]. No significant differ-
ence between the two combination treatments was
observed in terms of efficacy, safety, tolerance, fever clear-
ance, or haematological recovery. Moreover, no signifi-
cant difference in gametocyte prevalence was found
between the two combination treatments. The observed
lower prevalence of gametocytes in AQ+SP and AQ+AS
Proportions of parasitaemic patients following treatment Figure 3
Proportions of parasitaemic patients following treat-
ment. CQ, Chloroquine, AQ, Amodiaquine; SP, Sulfadoxine-
Pyrimethamine; AS, artesunate; On day 1, Significant differ-
ence to CQ group (P < 0.05), CQ vs. SP, CQ vs. AQ+AS; 
Significant difference to AQ group (P < 0.05), AQ vs. 
AQ+AS; Significant difference to AQ+SP group (P < 0.05), 
AQ+SP vs. AQ+AS; On day 2, Significant difference to SP 
group (P < 0.05), SP vs. CQ; Significant difference to AQ+AS 
group (P < 0.05), AQ+AS vs. CQ, AQ+AS vs. AQ, AQ+AS 
vs. SP, AQ+AS vs. AQ+SP; on day 14, Significant difference 
to CQ group (P < 0.05), CQ vs. AQ, CQ vs. SP, CQ vs. 
AQ+SP, CQ vs. AQ+AS; On day 21, Significant difference to 
CQ group (P < 0.05), CQ vs. AQ, CQ vs. AQ+SP, CQ vs. 
AQ+AS; On day 28, Significant difference to AQ+SP group (P 
< 0.05), AQ+SP vs. AQ+AS
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Table 3: Gametocyte prevalence on days 0, 7, 14, 21 and 28 after treatment in patients with adequate parasitological response
Gametocyte prevalence, %, (n/N)
After treatment
At enrolment Day 7 Day 14 Day 21 Day 28
CQ 4.7 (2/42) 12.5 (3/24)* 4.2 (1/24)* 6.6 (1/15) 0 (0/15)
AQ 12.8 (5/39) 13.1 (5/38)* 10.5 (4/38)* 9.6 (3/31) 0 (0/30)
SP 10.2 (4/39) 44.4 (16/36) 33.3 (12/36) 17.1 (6/35) 6.1 (2/33)
AQ+SP 2.4 (2/83) 3.8 (3/80)* 6.3 (5/80)* 1.3 (1/75)¶ 1.3 (1/75)
AQ+AS 3.6 (3/83) 2.5 (2/80)* 1.2 (1/79)* 1.5 (1/64)¶ 0 (0/64)
CQ, Chloroquine, AQ, amodiaquine; SP, Sulphadoxine-Pyrimethamine; AS, artesunate; 95% CI, 95% confidence interval.
* On day 7 and day 14, significant difference to SP group (P < 0.05)
¶On day 21, significant difference to SP group (P < 0.05)Malaria Journal 2007, 6:65 http://www.malariajournal.com/content/6/1/65
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groups reflect the effect of the additional drug on gameto-
cyte survival or development, as has been previously
shown for AQ+AS [14] and AQ+SP [9,25].
Although AQ+AS produced faster parasite clearance than
AQ+SP, the risk of new infection within the month after
therapy was high with AQ+AS than AQ+SP treatment,
even in a low transmission area such as Moramanga. This
phenomenon has previously been observed in areas of
high transmission [14,24]. According to Krishna [26] and
Watkins [27], the prevention of new infections by AQ+SP
is probably due to the long elimination half-lives of the
two drugs, whereas with AQ+AS combination, AS is rap-
idly eliminated, leaving only AQ to provide post-treat-
ment prophylaxis.
However, cost and availability of ACTs remain major con-
cerns, and it appears that the sudden increase in demand
for artemisinins may exacerbate these problems, at least in
the short-term [7]. AQ+AS (0.51 US$) [28] is currently
four times more expensive than AQ+SP (0.13 US$). In
Madagascar, with a reported 2,114,400 cases of suspected
malaria (2003), the use of AQ+SP instead of AQ+AS
would reduce the annual antimalarial treatments costs by
800,000 US$. In view of the recent report by Tagbor and
colleagues [29] there is hope that AQ+SP could serve as a
safe and effective alternative for malaria treatment in preg-
nancy and for intermittent preventive treatment until the
safety of ACTs for pregnant women has been established.
Moreover, further studies should be carry out to assess the
usefulness of AQ+SP pre-packed fixed-dose combination
as alternative of SP alone in intermittent preventive treat-
ment in infants and as alternative for CQ for the home
management of presumed malaria in children under five
years of age.
In conclusion, these results indicate that AQ+SP is as
effective as AQ+AS, and thereby show that the inexpensive
and widely available combination AQ+SP may still be
appropriate for the treatment of uncomplicated malaria in
Madagascar, an area where resistance to the drugs is rela-
tively uncommon. This could have an important role in
this country, where diagnostic services are not accurate
and where much of the drugs administered go to patients
who do not have malaria.
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